Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca pays $1bn for biotech that may 'transform cell therapy'
03:32am, Monday, 17'th Mar 2025
AstraZeneca PLC (LSE:AZN) has agreed to pay up to $1 billion to buy EsoBiotec, a Belgian company that has made clinical breakthroughs in cell therapy, where immune cells are engineered directly wit
AstraZeneca to buy Esobiotec for upto $1 billion
03:07am, Monday, 17'th Mar 2025
Drugmaker AstraZeneca on Monday said it will buy biotechnology firm Esobiotec for upto $1 billion.
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
03:00am, Monday, 17'th Mar 2025
Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potential to transform cell therapy Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potent
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
12:00pm, Friday, 14'th Mar 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
11:55am, Thursday, 13'th Mar 2025
This biopharmaceutical stock is nearing a buy point of a cup-with-handle base. The post AstraZeneca Stock Nears Buy Point After Long Run In Declining Market appeared first on Investor's Business Daily
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster
10:40am, Wednesday, 12'th Mar 2025
UBS has reaffirmed its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, with the bank is optimistic about the potential of its blood pressure drug, baxdrostat. The
AstraZeneca's Imfinzi success a step towards $80bn revenue aim - analyst
05:10am, Friday, 07'th Mar 2025
AstraZeneca PLC has edged closer to its aim of generating $80 billion in revenue come 2030 on positive results from a trial of Imfinzi, according to analysts. Shore Capital doubled down on a ‘buy' r
AstraZeneca's Imfinzi shows promise in early-stage stomach and oesophageal cancer
03:12am, Friday, 07'th Mar 2025
A new treatment combining AstraZeneca PLC's (LSE:AZN) drug Imfinzi with chemotherapy has shown promising results for people with early-stage stomach and oesophageal cancer, making it less likely that
6 Ideal Buys From 14 'Safer' March Dividends On Bloomberg 2025 Watch List Of 50
06:25pm, Wednesday, 05'th Mar 2025
Bloomberg Intelligence analysts identified 50 stocks for 2025, focusing on catalysts like new leadership, acquisitions, and AI advancements, with 35 paying dividends. 14 of these dividend-paying stock
AstraZeneca: A Big Pharma Blue Chip To Buy Now
07:00am, Wednesday, 05'th Mar 2025
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net d
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in HER2+ Metastatic Gastric Cancer.
WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen's TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
07:15pm, Friday, 28'th Feb 2025
In the closing of the recent trading day, Astrazeneca (AZN) stood at $76.21, denoting a +0.74% change from the preceding trading day.
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
10:01am, Friday, 28'th Feb 2025
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for a
